Invitation to presentation of Thor Medical ASA's first half results 2023

Oslo, 17 August 2023: Thor Medical ASA will release its first half results on Thursday 31 August 2023 at 07:00 am (CEST).

A presentation of the results followed by a Q&A session will be held on the same day at 08:00 am at Carnegie's offices at Aker Brygge, Fjordalleen 16, and through a live webcast. The presentation and the Q&A session can be followed through a live webcast from our website www.thormedical.no or Thor Medical webcast Q2 2023.

For further information, please contact:
Brede Ellingsæter, CFO, [email protected]  
Ludvik Sandnes, Chair of the Board, [email protected]

About Thor Medical 
Thor Medical is an emerging supplier of radionuclides, alpha particle emitters, for medical use in cancer therapy. Thor Medical has developed a proprietary technology for the manufacturing of alpha particle emitters from natural resources. Its novel production process requires no irradiation in nuclear reactors, and provides reliable, environmentally friendly supply of radionuclides for the radiopharmaceutical industry. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’. To learn more, visit www.thormedical.no.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act